NCT01371565

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Corcept Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.

Conditions

• Cushing's Disease
• Cushing's Syndrome

Interventions

Type	Name	Description
DRUG	Mifepristone	mifepristone at doses from 300mg/day up to 1200mg/day

Timeline

• Start date: 2010-11-01
• Primary completion: 2012-06-01
• Completion: 2012-09-01
• First posted: 2011-06-13
• Last updated: 2014-03-18
• Results posted: 2013-11-20

Locations

5 sites across 1 country: United States